INN Alteplase

Alteplase was included in the "list of strategically important medicines, the production of which should be provided on the territory of the Russian Federation" (Order of the Government of the Russian Federation of July 6, 2010 № 1141-p)

"GENERIUM" has developed and registered the first biosimilar of alteplase – Revelise®

Revelise® is used for the fibrinolytic treatment of acute ischemic stroke, acute myocardial infarction, acute massive pulmonary embolism.